Schizophrenia study finds new biomarker, drug candidate to treat cognitive symptoms

A new Northwestern University study in humans and mice has discovered a novel biomarker of schizophrenia that could also serve as a new drug candidate to treat the cognitive symptoms of the disorder. Schizophrenia affects .5% of the world’s population, including about two million people in the U.S.

Drug has only been tested in mice.

Of course, in this case the issue seems like it's caused by a general deficiency of single protein, maybe that's a good sign for adapting the treatment to humans.